Cargando…
Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report
Anti‐programmed cell death 1 (PD‐1) and its ligand (PD‐L1) has emerged as a novel immunotherapy for non‐small cell lung cancer (NSCLC). However, the proportion of patients who may benefit from immunotherapy is limited and the factors sensitive or resistant to immunotherapy are not completely clear....
Autores principales: | Tang, Yong, Li, Yadan, Zhang, Lei, Tong, Guihui, Ou, Zhu'an, Wang, Zhuocai, Zhang, Henghui, Qiao, Guibin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113060/ https://www.ncbi.nlm.nih.gov/pubmed/32077636 http://dx.doi.org/10.1111/1759-7714.13361 |
Ejemplares similares
-
MDM2 promotes epithelial–mesenchymal transition through activation of Smad2/3 signaling pathway in lung adenocarcinoma
por: Tang, Yong, et al.
Publicado: (2019) -
A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019) -
EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma
por: Chen, Zhiming, et al.
Publicado: (2020) -
Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency
por: Pang, Xionghao, et al.
Publicado: (2020) -
Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma
por: Fields, R C, et al.
Publicado: (2011)